IQVIA (NYSE:IQV) Announces Earnings Results, Beats Estimates By $0.08 EPS

IQVIA (NYSE:IQV) issued its quarterly earnings results on Tuesday. The medical research company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.26 by $0.08, FiscalAI reports. The business had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter last year, the firm posted $3.00 earnings per share. IQVIA’s revenue was up 8.0% compared to the same quarter last year.

Here are the key takeaways from IQVIA’s conference call:

• IQVIA exceeded third-quarter guidance, with revenue of $4.43 billion growing 8% reported, adjusted EBITDA up 8.7%, and adjusted EPS up 11.3% year over year. The company raised its full-year 2026 revenue, adjusted EBITDA, and adjusted EPS outlook.
• R&D Solutions delivered its strongest clinical bookings in four years, with $3.2 billion of net new bookings, a 1.2 book-to-bill ratio, and last-12-month bookings up 14% to $11.7 billion. Management cited broad-based strength, improving win rates, and renewed momentum in full-service outsourcing.
• Demand indicators remain favorable, including an 85% year-to-date increase in emerging biopharma funding, high-single-digit growth in clinical trial starts and RFP flow, and more than 40% growth in new drug launches. Commercial Solutions organic growth doubled from last year’s rate, while pipelines remain at record levels.
• AI adoption is becoming a meaningful competitive differentiator, with 415 agents deployed and customers using AI for trial design, site selection, market access, patient services, and commercial insights. Management said AI is supporting new revenue opportunities while also improving internal productivity and margins.
• The company removed approximately $2.1 billion of inactive trials from reported R&D backlog after reviewing studies inactive for roughly 18 months or more, although management said the adjustment does not affect historical results, 2026 guidance, bookings, or next-12-month revenue. IQVIA also ended the quarter with $13.8 billion of net debt and 3.45 times net leverage.

IQVIA Price Performance

Shares of IQV opened at $272.51 on Wednesday. The business’s 50-day moving average price is $264.74 and its 200 day moving average price is $209.94. IQVIA has a 1-year low of $154.50 and a 1-year high of $284.50.

More IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: IQVIA reported third-quarter adjusted earnings of $3.34 per share, above analyst expectations of approximately $3.24–$3.26. Revenue increased 8% year over year to $4.428 billion, exceeding estimates near $4.37 billion. IQVIA Reports Third-Quarter 2026 Results
• Positive Sentiment: Strong demand in the company’s R&D Solutions segment, particularly clinical services, drove the performance. IQVIA said trailing-12-month clinical bookings reached $11.7 billion, described as the strongest level since 2022, supporting expectations for future revenue growth. IQVIA gains as R&D Solutions drive Q3 beat
• Positive Sentiment: Management raised or reaffirmed an improved full-year outlook, signaling 2026 revenue of $17.35 billion to $17.50 billion and adjusted EPS of $12.90 to $13.00. The earnings beat and improved execution prompted a favorable analyst view. IQVIA raises full-year guidance
• Neutral Sentiment: The revenue outlook’s midpoint is close to the FactSet consensus estimate of $17.41 billion, making the guidance supportive but not a major upside surprise. IQVIA 2026 revenue outlook
• Negative Sentiment: Despite the earnings and revenue beats, shares were reported lower before the market open, suggesting investors may have expected a larger guidance increase or are taking profits after IQVIA’s strong recent run toward its 52-week high. IQVIA Q3 adjusted earnings and revenue rise

Analyst Ratings Changes

Several brokerages have recently issued reports on IQV. Stifel Nicolaus lifted their price objective on shares of IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Weiss Ratings raised shares of IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Leerink Partners raised their target price on shares of IQVIA from $280.00 to $310.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. HSBC lifted their price target on shares of IQVIA from $280.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, September 1st. Finally, UBS Group began coverage on shares of IQVIA in a research report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $283.00.

Insider Buying and Selling at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 10,023 shares of company stock valued at $2,413,394. 1.70% of the stock is currently owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.